Company intelligence / Profile preview
EmpathBio
New York, New York, United Statesempathbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
EmpathBio’s lead program EMP‑01 entered Phase I clinical trials in late September 2022. The goal is to create safer, more tolerable versions of MDMA that retain therapeutic benefits while reducing cardiovascular and stimulant side effects. No published efficacy results yet—trials are ongoing.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (specifically MDMA derivatives)Digital therapeutics adjuncts
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on EmpathBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EmpathBio.